2023 / 02

DOI: 10.47183/mes.2023.021

ОБЗОР

Особенности курации спортсменов при затяжных вариантах течения COVID-19

Л. А. Балыкова1, А. В. Жолинский2, М. С. Тарасова2, С. А. Ивянский1, С. А. Базанович2, М. В. Ширманкина1, Р. А. Беспалов1, П. В. Ефимов3, Ж. В. Гришина2, С. А. Парастаев2,3
Информация об авторах

1 Мордовский государственный университет имени Н. П. Огарева, Саранск, Россия

2 Федеральный научно-клинический центр спортивной медицины и реабилитации Федерального медико-биологического агентства, Москва, Россия

3 Российский национальный исследовательский медицинский университет имени Н. И. Пирогова Минздрава России, Москва, Россия

Для корреспонденции: Мария Сергеевна Тарасова
ул. Б. Дорогомиловская, д. 5, г. Москва, 121059, Россия; ur.abmftrops@smavosarat

Информация о статье

Финансирование: статья подготовлена в рамках прикладной научно-исследовательской работы «Изучение влияния новой коронавирусной инфекции COVID-19 на здоровье и функциональное состояние высококвалифицированных спортсменов и разработка методических рекомендаций по обследованию спортсменов, включая несовершеннолетних, по допуску спортсменов к тренировкам и соревнованиям после перенесенного заболевания COVID-19, по восстановлению их здоровья и функционального состояния» (шифр «COVID-22»), выполняемой ФГБУ ФНКЦСМ ФМБА России по государственному контракту №107.003.22.14 от 25 июля 2022 г.

Вклад авторов: Л. А. Балыкова — разработка концепции, написание текста, редактирование; А. В. Жолинский — разработка концепции, редактирование; М. С. Тарасова, М. В. Ширманкина, Ж. В. Гришина — поиск и анализ источников, написание текста; С. А. Ивянский, Р. А. Беспалов — поиск и анализ источников, разработка инструмента математического моделирования, написание текста; С. А. Базанович — определение подходов к математическому моделированию и их оптимизация; П. В. Ефимов — поиск и анализ источников, определение подходов к математическому моделированию и их оптимизация, написание текста; С. А. Парастаев — поиск и анализ источников, редактирование.

Статья получена: 25.05.2023 Статья принята к печати: 20.06.2023 Опубликовано online: 30.06.2023
|
  1. Zholinsky AV, Kruglova IV, Feshchenko VS, Risukhina YV, Fomin AV, Galaktionova NM, et al. Federal medical biological agency of Russia's efforts to support Russian athletes during COVID-19 outbreak. Sport Sci Health. 2022; 18 (3): 831–7. DOI: 10.1007/ s11332-021-00861-5. Epub 2021 Nov 6. PMID: 34777596; PMCID: PMC8571973.
  2. World Health Organization. Available from: https://www.who.int/ europe/emergencies/situations/covid-19
  3. Амиров Н. Б., Давлетшина Э. И., Васильева А. Г., Фатыхов Р. Г. Постковидный синдром: мультисистемные «дефициты». Вестник современной клинической медицины. 2021; 14 (6).
  4. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22 (4): e102–e107. DOI: 10.1016/S1473-3099(21)00703-9. Epub 2021 Dec 21. PMID: 34951953; PMCID: PMC8691845.
  5. Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022; 28 (5): 657–66. DOI: 10.1016/j.cmi.2022.01.014. Epub 2022 Feb 3. PMID: 35124265; PMCID: PMC8812092.
  6. Perrone MA, Volterrani M, Manzi V, Barchiesi F, Iellamo F. Heart rate variability modifications in response to different types of exercise training in athletes. J Sports Med Phys Fitness. 2021; 61 (10): 1411–5. DOI: 10.23736/S0022-4707.21.12480-6. Epub 2021 Jun 17 PMID: 34137572.
  7. Powell AW, Urbina EM, Orr WB, Hansen JE, Baskar S. EKG abnormalities in a youth athlete following COVID-19: it's not always myocarditis! Pediatr Cardiol. 2022; 43 (8): 1922–5. DOI: 10.1007/s00246-022-02935-8. Epub 2022 May 27. PMID: 35622085; PMCID: PMC9136195.
  8. Tanacli R, Doeblin P, Götze C, Zieschang V, Faragli A, Stehning C, et al. COVID-19 vs. Classical myocarditis associated myocardial injury evaluated by cardiac magnetic resonance and endomyocardial biopsy. Front Cardiovasc Med. 2021; 8: 737257. DOI: 10.3389/ fcvm.2021.737257. PMID: 35004872; PMCID: PMC8739473
  9. Wulf HS, Abbafati C, Aerts JG, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. medRxiv. 2022.
  10. Oikonomou E, Lampsas S, Theofilis P, Souvaliotis N, Papamikroulis GA, Katsarou O, et al. Impaired left ventricular deformation and ventricular-arterial coupling in post-COVID-19: association with autonomic dysregulation. Heart Vessels. 2023; 38 (3): 381–93. DOI: 10.1007/s00380-022-02180-2. Epub 2022 Sep 28.
  11. Antonelli M, et al. Risk factors and disease profile of postvaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022; 22: 43–55
  12. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. 2021. DOI: 10.1101/2021.10.26.21265508. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.10.26.21265508.
  13. Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France. 2022. DOI: 10.21203/rs.3.rs-1350429/ v1. Available from: https://www.researchsquare.com/article/rs1350429/v1\.
  14. Ashton RE, Philips BE, Faghy M. The acute and chronic implications of the COVID-19 virus on the cardiovascular system in adults: A systematic review. Prog Cardiovasc Dis. 2023; 76: 31–37. DOI: 10.1016/j.pcad.2023.01.003.
  15. Sandoval Y, Januzzi JL, Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am CollCardiol. 2020; 76: 1244–58.
  16. Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324: 603–5.
  17. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021; 4.
  18. Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am CollCardiol. 2020; 76: 2043–55.
  19. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020; 5: 1265–73.
  20. O'Connor FG. COVID-19: Return to sport or strenuous activity following infection. UpToDate. Literature review current through: May 2022. This topic last updated: Mar 28, 2022.
  21. Ali-Ahmed F, Dalgaard F, Al-Khatib SM. Sudden cardiac death in patients with myocarditis: evaluation, risk stratification, and management. Am Heart J. 2020; 220: 29–40.
  22. Phelan D, Kim JH, Elliott MD, et al. Screening of potential cardiac involvement in competitive athletes recovering from COVID-19: an expert consensus statement. JACC Cardiovasc Imaging. 2020; 13 (12): 2635–52. DOI: 10.1016/j.jcmg.2020.10.005.
  23. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019; 40 (1): 19–33.
  24. Wilson MG, Hull JH, Rogers J, et al. Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians. Br J Sports Med. 2020; 54 (19): 1157–61. DOI: 10.1136/bjsports-2020-102710.
  25. Dove J, Gage A, Kriz P, Tabaddor RR, Owens BD. COVID-19 and review of current recommendations for return to athletic play. R I Med J. 2020; 103 (7): 15–20. Published 2020 Sep 1.
  26. Moulson N, Petek BJ, Drezner JA, et al. SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. Circulation. 2021; 144 (4): 256–66. DOI: 10.1161/CIRCULATIONAHA.121.054824.
  27. Kim JY, Han K, Suh YJ. Prevalence of abnormal cardiovascular magnetic resonance findings in recovered patients from COVID-19: a systematic review and meta-analysis. J Cardiovasc Magn Reson. 2021; 23 (1): 100. DOI: 10.1186/s12968-02100792-7.
  28. Van Hattum JC, Spies JL, Verwijs SM, et al. Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review. BMJ Open Sport Exerc Med. 2021; 7 (4): e001164. Published 2021 Oct 12. DOI: 10.1136/bmjsem-2021-001164.
  29. Kelle S, Bucciarelli-Ducci C, Judd RM, et al. Society for Cardiovascular Magnetic Resonance (SCMR) recommended CMR protocols for scanning patients with active or convalescent phase COVID-19 infection. J Cardiovasc Magn Reson. 2020; 22: 61.
  30. Małek LA, Bucciarelli-Ducci C. Myocardial fibrosis in athletesCurrent perspective. Clin Cardiol. 2020; 43 (8): 882–8.
  31. Ahmad SA, Khalid N, Shlofmitz E, Chhabra L. Myocardial fibrosis and arrhythmogenesis in elite athletes. Clin Cardiol. 2019; 42 (9): 788.
  32. Zhang CD, Xu SL, Wang XY, Tao LY, Zhao W, Gao W. Prevalence of myocardial fibrosis in intensive endurance training athletes: a systematic review and meta-analysis. Front Cardiovasc Med. 2020; 7: 585692.
  33. Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021; 6 (1): 116–8. DOI: 10.1001/jamacardio.2020.4916.
  34. Gluckman TJ, Bhave NM, Allen LA, et al. 2022 ACC Expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022; 79 (17): 1717–56.
  35. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021; 6: 1078–87.
  36. Brito D, Meester S, Yanamala N, et al. High prevalenceof pericardial involvement in college studentathletes recovering from COVID-19. J Am Coll Cardiol Img. 2021; 14: 541–55.
  37. Clark DE, Parikh A, Dendy JM, et al. COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR). Circulation. 2021; 143: 609–12.
  38. Hwang CE, Kussman A, Christle JW, et al. Findingsfrom cardiovascular evaluation of National Collegiate Athletic Association Division I collegiate studentathletesafter asymptomatic or mildly symptomatic SARS-CoV-2 infection. Clin J Sport Med. Published online June 24, 2021.
  39. Starekova J, Bluemke DA, Bradham WS, et al. Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol. 2021; 6: 945–50.
  40. Martinez MW, Tucker AM, Bloom OJ, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol. 2021; 6: 745–52.
  41. Valverde I, Singh Y, Sanchez-de-Toledo J, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021; 143: 21–32.
  42. Sirico D, Basso A, Reffo E, et al. Early echocardiographic and cardiac MRI findings in multisystem inflammatory syndrome in children. J Clin Med. 2021; 10 (15): 3360.
  43. Palabiyik F, Akcay N, Sevketoglu E, et al. Imaging of multisystem inflammatory disein children (MIS-C) associated With COVID-19. Acad Radiol. 2021; 28: 1200–8.
  44. Cavigli L, et al. A prospective study on the consequences of SARSCoV-2 infection on the heart of young adult competitive athletes: implications for a safe return-to-play. International journal of cardiology. 2021; 336: 130–6. DOI: 10.1016/j.ijcard.2021.05.042.
  45. Modica G, Bianco M, Sollazzo F, et al. Myocarditis in athletes recovering from COVID-19: a systematic review and metaanalysis. Int J Environ Res Public Health. 2022; 19 (7): 4279.
  46. Ibarrola M, Dávolos I. Myocarditis in athletes after COVID-19 infection: the heart is not the only place to screen. Sports Med Health Sci. 2020; 2: 172–3.
  47. Chevalier L, Cochet H, Mahida S, et al. ASCCOVID investigators. Resuming training in high-level athletes after mild COVID-19 infection: a multicenter prospective study (ASCCOVID-19). Sports Med Open. 2022; 8 (1): 83. DOI: 10.1186/s40798-022-00469-0.
  48. Gamal DM, Ibrahim RA, Samaan SF. Post COVID-19 syndrome in a prospective cohort study of Egyptian patients. Egypt Rheumatol Rehabil. 2022; 49 (1): 12. Available from: https://doi.org/10.1186/ s43166-021-00104-y.
  49. Nabavi N. Long COVID: how to define it and how to manage it. BMJ. 2020; 370: m3489. Published 2020 Sep 7. DOI: 10.1136/ bmj.m3489.
  50. Giusto E, Asplund CA. Persistent COVID and a return to sport. Curr Sports Med Rep. 2022; 21 (3): 100–4.
  51. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021; 69 (2): 205–11. DOI: 10.1007/s12026-021-09185-5.
  52. Phelan D, Kim JH, Chung EH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. JAMA Cardiol. 2020; 5: 1085–6.
  53. Baggish A, Drezner JA, Kim J, Martinez M, Prutkin JM. The resurgence of sport in the wake of COVID-19: cardiac considerations in competitive athletes. Br J SportsMed. 2020; 54: 1130–1.
  54. Kim JH, Levine BD, Phelan D, et al. Coronavirus disease 2019 and the athletic heart: emerging perspectives on pathology, risks, and return to play. JAMA Cardiol. 2021; 6: 219–27.
  55. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020; 383: 334–46.
  56. Maron BJ, Udelson JE, Bonow RO. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015; 66: 2362–71.